Block listing 6 Monthly Return
Shield Therapeutics plc has provided a six-monthly return for its share schemes, reporting a balance of 39,794 unallotted securities under the Retention Share Plan and 341,020 under the 2016 Company Share Option Plan, with no changes during the period from July 1, 2025, to December 31, 2025. The 2016 Long Term Incentive Plan also shows no activity, maintaining a balance of 24,273 unallotted securities. However, the Retention and Performance Share Plan saw an increase of 15,000,000 securities, with 6,137,791 issued, resulting in a closing balance of 11,733,071 unallotted securities.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
|---|---|---|---|---|
| Name of scheme: | Shield Therapeutics Retention Share Plan | |||
| Period of return: | From: | 01 July 2025 | To: | 31 December 2025 |
| Balance of unallotted securities under scheme(s) from previous return: | 39,794 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 39,794 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | Shield Therapeutics plc 2016 Company Share Option Plan | |||
| Period of return: | From: | 01 July 2025 | To: | 31 December 2025 |
| Balance of unallotted securities under scheme(s) from previous return: | 341,020 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 341,020 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | The Shield Therapeutics plc 2016 Long Term Incentive Plan | |||
| Period of return: | From: | 01 July 2025 | To: | 31 December 2025 |
| Balance of unallotted securities under scheme(s) from previous return: | 24,273 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 24,273 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | Shield Therapeutics Retention and Performance Share Plan | |||
| Period of return: | From: | 01 July 2025 | To: | 31 December 2025 |
| Balance of unallotted securities under scheme(s) from previous return: | 2,870,838 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 15,000,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 6,137,791 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 11,733,071 | |||
| Name of contact: | Lucy Huntington-Bailey | |||
| Telephone number of contact: | +44 (0) 191 511 8500 |
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.